This Article Full Text Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schaefer, J. R. Articles by Marz, W. Search for Related Content PubMed PubMed Citation Articles by Schaefer, J. R. Articles by Marz, W.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 1997;17:348-353.)
© 1997 American Heart Association, Inc.

Articles

Homozygous Familial Defective Apolipoprotein B-100

Enhanced Removal of Apolipoprotein E–Containing VLDLs and Decreased Production of LDLs

Juergen R. Schaefer; Hubert Scharnagl; Manfred W. Baumstark; Horst Schweer; Loren A. Zech¹; Hansjorg Seyberth; Karl Winkler; Armin Steinmetz; Winfried Marz

the Division of Cardiology, Department of Medicine, Philipps-University Marburg, (J.R.S., H. Schweer, H. Seyberth, A.S.), the Division of Clinical Chemistry (H. Scharnagl, K.W., W.M.), and the Division of Sports Medicine (M.W.B.), Department of Medicine, Albert Ludwigs-University, Freiburg, Germany, and the Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md (L.A.Z.).

Familial defective apolipoprotein B-100 (FDB) is a frequently inherited disorder of lipoprotein metabolism. The glutamine-for-arginine substitution at position 3500 of apolipoprotein (apo) B-100 leads to defective binding of apo B-100 to the low density lipoprotein (LDL) receptor and accumulation of LDL in the plasma. We recently identified a patient homozygous for this mutation. His LDL cholesterol and apo B concentrations were approximately twice normal, whereas his apo E plasma level was low. Using a stable-isotope labeling technique ([²H₃]leucine–primed constant infusion), we studied lipoprotein turnover in vivo in the fasting state in this patient and three clinically healthy, normolipidemic individuals not carrying the FDB mutation. The residence time of LDL apo B-100 was prolonged 3.6-fold in the FDB homozygote (8.3 vs 2.3 days). The production rate of LDL apo B-100 was decreased (7.4 vs 15 mg per kg per day). In FDB the residence time of very low density lipoprotein (VLDL) apo B-100 was longer (2.6 vs 1.3 hours), whereas the residence time of VLDL apo E was shorter (2.6 vs 4.5 hours) than normal. These data show that the in vivo metabolism of apo B-100–containing lipoproteins in FDB is different from that in familial hypercholesterolemia, in which LDL receptors are defective. In both conditions the residence times of LDL apo B-100 appear to be increased to approximately the same degree. This contrasts with the LDL apo B-100 synthetic rate, which is increased in familial hypercholesterolemia and decreased in FDB. The decreased production of LDL apo B-100 in FDB may originate from enhanced removal of apo E–containing LDL precursors by LDL receptors, which may be upregulated in response to the decreased flux of LDL-derived cholesterol into hepatocytes.

Key Words: hypercholesterolemia • apolipoprotein B-100 • atherosclerosis • genetic disease • stable-isotope tracer kinetics

This article has been cited by other articles:

				L. A. Johnson, M. K. Altenburg, R. L. Walzem, L. T. Scanga, and N. Maeda Absence of Hyperlipidemia in LDL Receptor-Deficient Mice Having Apolipoprotein B100 Without the Putative Receptor-Binding Sequences Arterioscler. Thromb. Vasc. Biol., October 1, 2008; 28(10): 1745 - 1752. [Abstract] [Full Text] [PDF]

				A. Garg and V. Simha Update on Dyslipidemia J. Clin. Endocrinol. Metab., May 1, 2007; 92(5): 1581 - 1589. [Abstract] [Full Text] [PDF]

				R. Ramakrishnan Studying apolipoprotein turnover with stable isotope tracers: correct analysis is by modeling enrichments J. Lipid Res., December 1, 2006; 47(12): 2738 - 2753. [Abstract] [Full Text] [PDF]

				K. G. Parhofer and P. H. R. Barrett Thematic review series: Patient-Oriented Research. What we have learned about VLDL and LDL metabolism from human kinetics studies J. Lipid Res., August 1, 2006; 47(8): 1620 - 1630. [Abstract] [Full Text] [PDF]

				K. Ikewaki, J. R. Schaefer, M. E. Frischmann, K. Okubo, T. Hosoya, S. Mochizuki, B. Dieplinger, E. Trenkwalder, H. Schweer, F. Kronenberg, et al. Delayed In Vivo Catabolism of Intermediate-Density Lipoprotein and Low-Density Lipoprotein in Hemodialysis Patients as Potential Cause of Premature Atherosclerosis Arterioscler. Thromb. Vasc. Biol., December 1, 2005; 25(12): 2615 - 2622. [Abstract] [Full Text] [PDF]

				J. R. Schaefer, K. Winkler, H. Schweer, M. M. Hoffmann, M. Soufi, H. Scharnagl, B. Maisch, H. Wieland, A. Steinmetz, and W. Marz Increased Production of HDL ApoA-I in Homozygous Familial Defective ApoB-100 Arterioscler. Thromb. Vasc. Biol., July 1, 2000; 20(7): 1796 - 1799. [Abstract] [Full Text] [PDF]

				D. Gaffney, C. Pullinger, J. Kane, J. R. Schaefer, M. Herzum, B. Maisch, A. Tybjarg-Hansen, and B. G. Nordestgaard Association of Mutations in the Apolipoprotein B Gene with Hypercholesterolemia and the Risk of Ischemic Heart Disease N. Engl. J. Med., November 26, 1998; 339(22): 1640 - 1642. [Full Text]